Neuroprotection by Exendin-4 Is GLP-1 Receptor Specific but DA D3 Receptor Dependent, Causing Altered BrdU Incorporation in Subventricular Zone and Substantia Nigra

Journal of Neurodegenerative Diseases
Alexander HarkavyiPeter S Whitton

Abstract

Glucagon-like peptide-1 receptor (GLP-1R) activation by exendin-4 (EX-4) is effective in preclinical models of Parkinson's disease (PD) and appears to promote neurogenesis even in severely lesioned rats. In the present study, we determined the effects of EX-4 on cellular BrdU incorporation in the rat subventricular zone (SVZ) and substantia nigra (SN). We also determined the specificity of this effect with the GLP-1R antagonist EX-(9-39) as well as the potential role of dopamine (DA) D3 receptors. Rats were administered 6-OHDA and 1 week later given EX-4 alone, with EX-(9-39) or nafadotride (D3 antagonist) and BrdU. Seven days later, rats were challenged with apomorphine to evaluate circling. Extracellular DA was measured using striatal microdialysis and subsequently tissue DA measured. Tyrosine hydroxylase and BrdU were verified using immunohistochemistry. Apomorphine circling was reversed by EX-4 in lesioned rats, an effect reduced by EX-4, while both EX-(9-39) and NAF attenuated this. 6-OHDA decreased extracellular and tissue DA, both reversed by EX-4 but again attenuated by EX-(9-39) or NAF. Analysis of BrdU+ cells in the SVZ revealed increases in 6-OHDA-treated rats which were reversed by EX-4 and antagonised by either EX-...Continue Reading

References

Jun 26, 2001·Brain Research·D W AndersonJ S Schneider
Nov 1, 2002·The Journal of Biological Chemistry·Yazhou LiDaniel J Drucker
Mar 12, 2003·International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity·A J Kastin, V Akerstrom
Jun 7, 2003·Proceedings of the National Academy of Sciences of the United States of America·Ming ZhaoAnn Marie Janson
Sep 5, 2003·European Journal of Pharmacology·Andres D RamirezFrank S Menniti
May 7, 2004·The European Journal of Neuroscience·Jackalina M Van KampenHarold A Robertson
Jun 15, 2004·Nature Neuroscience·Günter U HöglingerEtienne C Hirsch
Jun 24, 2004·Proceedings of the National Academy of Sciences of the United States of America·Helena FrielingsdorfPaul Mohapel
Feb 24, 2006·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Nils FreundliebGünter U Höglinger
Jul 11, 2006·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Jackalina M Van Kampen, Christopher B Eckman
Feb 26, 2008·Cell·Chunmei ZhaoFred H Gage
Jan 24, 2009·Proceedings of the National Academy of Sciences of the United States of America·Yazhou LiNigel H Greig
Feb 5, 2010·British Journal of Pharmacology·Alexander Harkavyi, Peter S Whitton
May 19, 2010·Journal of Neurochemistry·Yongsoo KimFrancis G Szele
Jun 4, 2013·The Journal of Clinical Investigation·Iciar Aviles-OlmosThomas Foltynie

❮ Previous
Next ❯

Citations

Apr 17, 2021·ACS Pharmacology & Translational Science·Vicki WangYuan-Hao Chen
Aug 10, 2019·ACS Pharmacology & Translational Science·Elliot J GlotfeltyNigel H Greig

❮ Previous
Next ❯

Methods Mentioned

BETA
dissection

Software Mentioned

GraphPad Prism
Chromperfect

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.